HeartLung.AI to present eight abstracts at AHA 2026 in Chicago

HeartLung.AI will present eight accepted abstracts at the American Heart Association Scientific Sessions 2026, Nov. 6-9 at McCormick Place in Chicago. The research focuses on using AI to extract more preventive risk information from routine imaging, and the company will also be at Booth 641 during the exhibit hall dates.

Why it matters: - HeartLung.AI is pushing a preventive-screening model that treats one scan as a source of multiple risk signals, not a single report. - The research could help identify coronary, cardiac, lung and cardiometabolic risk earlier from imaging people already receive in routine care. - The company is using the AHA meeting to show how AI may expand the clinical value of coronary calcium scans and chest CTs without new hardware.

What happened: - HeartLung Corporation will present eight accepted scientific abstracts at the American Heart Association Scientific Sessions 2026 in Chicago from Nov. 6-9 at McCormick Place. - The abstract set covers coronary plaque assessment, AI-based calcium scoring, cardiac chamber analysis, lung cancer risk assessment and cardiovascular prediction from routine chest X-rays. - Morteza Naghavi, MD, founder and president of HeartLung Corporation, said the company sees the future of preventive screening as “one scan, many answers.” - HeartLung.AI will be at Booth 641 in the AHA Science & Technology Hall during the exhibit hall dates, Nov. 7-9.

The details: - Abstract 1 compares investigational AI-CAC plaque analysis from non-contrast coronary artery calcium scans with AI quantitative coronary CT findings from contrast-enhanced coronary CT angiography. - Abstract 2 examines whether Agatston-2.0 measurements relate to non-calcified coronary plaque burden among people with a conventional CAC score of zero in the Miami Heart Study. - Abstract 3 studies whether AI-derived calcium burden and plaque density improve coronary heart disease risk stratification in patients with CAC scores of 1-99. - Abstract 4 uses the Multi-Ethnic Study of Atherosclerosis to assess plaque density characteristics across coronary calcium burden strata. - Abstract 5 evaluates changes in AI-measured cardiac chamber volumes on CAC scans and their link to later cardiovascular disease in MESA. - Abstract 6 compares AI-derived imaging biomarkers from CAC scans with conventional risk factors for predicting cardiovascular disease. - Abstract 7 compares opportunistic AI detection of lung cancer on CAC scans with full-lung CT scans in MESA and the Framingham Heart Study. - Abstract 8 uses the MIMIC cohort to assess cardiovascular risk signals on routine chest X-rays, including links to atherosclerotic events, heart failure and atrial fibrillation. - Exhibit hours for Booth 641 are Saturday, Nov. 7 from 9:00 a.m. to 4:30 p.m. CT, Sunday, Nov. 8 from 9:00 a.m. to 4:30 p.m. CT, and Monday, Nov. 9 from 9:00 a.m. to 3:00 p.m. CT. - HeartLung.AI invites attendees to discuss clinical validation, collaboration and responsible implementation of opportunistic screening. - Conference meetings can be requested at more information or by email at contact@heartlung.ai.

Between the lines: - The abstract list shows HeartLung.AI is trying to broaden the use of existing imaging beyond traditional calcium scoring. - Several studies target groups where current scores can miss risk, including people with zero CAC and those with low CAC scores. - The company is also testing whether limited-field scans and even chest X-rays can surface actionable findings, which would matter if validated in broader clinical use. - The mix of MESA, Framingham, Miami Heart Study and MIMIC suggests the company is emphasizing evidence generation across multiple cohorts rather than a single dataset.

What's next: - HeartLung.AI will present the abstracts during AHA Scientific Sessions 2026 in Chicago. - The company will use Booth 641 to discuss workflows, validation and collaboration during the exhibit hall period. - HeartLung.AI says its broader platform vision is to extend opportunistic imaging toward earlier insight into heart disease, lung cancer, COPD, osteoporosis, fatty liver disease and other conditions detectable on coronary calcium scans and routine chest CTs. - The company’s cloud platform connects with existing PACS or accepts direct scan uploads and produces AI-generated DICOM and PDF reports.

The bottom line: - HeartLung.AI is betting that AI can turn commonly acquired scans into a wider preventive-screening tool, with eight AHA abstracts designed to support that case.